University of Minnesota / Masonic Cancer Center
Welcome,         Profile    Billing    Logout  
 13 Trials 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moertel, Christopher
NCT03975829 / 2018-004459-19: Pediatric Long-Term Follow-up and Rollover Study

Active, not recruiting
4
165
Europe, Canada, Japan, US, RoW
dabrafenib, DRB436, trametinib, TMT212
Novartis Pharmaceuticals, Novartis Pharma AG
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
05/26
05/26
POPLAR-NF2, NCT05130866: Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Recruiting
2/3
92
US
REC-2282, AR-42, OSU-HDAC42, NSC-D736012, Placebo
Recursion Pharmaceuticals Inc.
Neurofibromatosis Type 2
01/27
07/27
RENEU, NCT03962543: MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Hourglass Jan 2022 - Dec 2022 : Data from RENEU trial for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas
Checkmark Data from RENEU trial for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas
Feb 2021 - Feb 2021: Data from RENEU trial for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas
Active, not recruiting
2
114
US
Mirdametinib (PD-0325901) oral capsule or dispersible tablet, PD-0325901, Mirdametinib
SpringWorks Therapeutics, Inc.
Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)
09/23
05/25
Alonso, Jose Luis
POPLAR-NF2, NCT05130866: Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Recruiting
2/3
92
US
REC-2282, AR-42, OSU-HDAC42, NSC-D736012, Placebo
Recursion Pharmaceuticals Inc.
Neurofibromatosis Type 2
01/27
07/27
NCT05123755: Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

Recruiting
2a
120
US
AV-001 Injection, AV-001 Placebo Injection
Vasomune Therapeutics, Inc.
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral, Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
12/24
03/25
TORCH, NCT04187872: LITT and Pembrolizumab in Recurrent Brain Metastasis

Terminated
1
10
US
LITT + Pembrolizumab, NeuroBlate System, Keytruda
University of Florida, Monteris Medical
Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Brain Metastases, Adult
12/23
12/23
NCT05518838: Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

No Longer Available
N/A
US
OKN-007
Oblato, Inc.
Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
 
 
VIVA, NCT04861805: Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System

Recruiting
N/A
150
Europe, RoW
Vienna Aortic Valve SE System
P+F Products + Features GmbH, Meditrial USA Inc.
Symptomatic Aortic Stenosis
07/25
10/30
Fullenkamp, Allison
POPLAR-NF2, NCT05130866: Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Recruiting
2/3
92
US
REC-2282, AR-42, OSU-HDAC42, NSC-D736012, Placebo
Recursion Pharmaceuticals Inc.
Neurofibromatosis Type 2
01/27
07/27

Download Options